DMC Biotechnologies has completed downstream processing for its first product, the amino acid L-alanine. Processing was done at EW Biotech in Leuna, Germany, following the successful demonstration of commercial scale fermentation at the same site in March.
The purification of L-alanine from the fermentation broth was completed for more than 6,000 kg of product, and testing has confirmed the customer specifications for the amino acid were met, DMC says.
Demonstration of the purification process and achievement of product specifications is the final proof point for DMC’s approach to producing L-alanine. As announced on 21 April 2021, the product is now available at commercial scale following execution of a manufacturing agreement with Conagen.
Matt Lipscomb, PhD, CEO & co-founder of DMC said: “We recently announced the successful full commercial-scale demonstration of our fermentation process. Historically, fermentation scale-up has been a major stumbling block for early-stage companies. Delivering products to customers also requires successful purification and demonstration that the product meets the required specifications. We now have product with demonstrated quality metrics enabling customer adoption.”
Dr -Ing. Markus Fritsch, Senior Project Manager at EW Biotech said: “It was a demanding project at a very unusual time. Preparations for the downstream processing (DSP) implementation in our facility went in parallel to the fermentation scale-up activities. With the deep contributions from our network of long-term partners we were able to deliver product that met target specifications. Thanks to DMC and our operating team at EW Biotech for making this project a joint success.”
